SCHEMBL2140956

SCHEMBL2140956

CCOc1cc(-c2c(CC)cccc2CC)nc(C)c1COc1cccc(CN2CCOCC2)c1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.43
HTT P42858 4/20 0.43
KDM4E B2RXH2 4/20 0.43
HPGD P15428 1/20 0.43
HTR1A P08908 1/20 0.41
DRD2 P14416 1/20 0.41
HTR2B P41595 1/20 0.41
CD274 Q9NZQ7 1/20 0.41
HRH3 Q9Y5N1 3/20 0.41
PDE2A O00408 1/20 0.40
USP7 Q93009 1/20 0.40
DDB1 Q16531 1/20 0.39
CRBN Q96SW2 1/20 0.39
ACHE P22303 1/20 0.39
PARP1 P09874 1/20 0.39
FAAH O00519 1/20 0.38
RECQL P46063 1/20 0.38
LMNA P02545 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1329649 0.77 PTGS1 (0.40) HTTLMNA
SCHEMBL1327007 0.77 ALDH1A1 (0.41) ALDH1A1HTTKDM4EHPGDHTR1A
SCHEMBL1328958 0.76 CYP2A13 (0.47) ALDH1A1HTTKDM4EHPGDLMNA
SCHEMBL12124941 0.76 ALDH1A1 (0.68) ALDH1A1HTTKDM4EHPGDHTR1A
SCHEMBL1328014 0.76 HTR1A (0.39) HTR1AHTR2BCD274
SCHEMBL1328338 0.75 C5AR1 (0.41) ALDH1A1HTTKDM4EHPGDCD274
SCHEMBL1327010 0.75 PPARG (0.47)
SCHEMBL1329576 0.74 ABCB1 (0.41) HTTHTR1ADRD2
SCHEMBL1327243 0.74 PPARG (0.47) ALDH1A1HPGDLMNA
SCHEMBL1328682 0.73 BCHE (0.45) ALDH1A1HTTACHERECQLLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7863454-B2 3-substituted-6-aryl pyridines NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2011-01-04 US disclosed
US-20090176980-A1 3-Substituted-6-Aryl Pyridines NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2009-07-09 US disclosed
US-7342115-B2 Binding antagonist and arylpyridine for antiinflammatory agents, cardiovascular disorders and antagonist or agonist and for immunology NEUROGEN CORPORATION (US) 2008-03-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090176980-A1 3-Substituted-6-Aryl Pyridines C3AR1, C5AR1, C5AR2 ALDH1A1 1966/4885HTT 4493/4885KDM4E 2088/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.